Aduro gets $200m as Novartis steps up immuno-oncology

Aduro Biotech has secured a $200m upfront payment from Novartis as the latter steps up its activity in immunotherapy for cancer. The deal brings Novartis an early-stage immuno-oncology platform targeting the Stimulator of Interferon Genes (STING) pathway, adding to its ongoing programs using chimeric antigen receptor T-cell (CART) technology and checkpoint inhibitors.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

01 May 2025

• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.